Leslie Norwalk Sells 1,250 Shares of Neurocrine Biosciences (NASDAQ:NBIX) Stock

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Director Leslie Norwalk sold 1,250 shares of the stock in a transaction that occurred on Thursday, June 4th. The stock was sold at an average price of $168.06, for a total value of $210,075.00. Following the completion of the transaction, the director owned 2,838 shares in the company, valued at approximately $476,954.28. The trade was a 30.58% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Neurocrine Biosciences Stock Down 0.5%

NASDAQ:NBIX traded down $0.76 on Monday, hitting $163.12. The stock had a trading volume of 804,512 shares, compared to its average volume of 1,180,765. The business’s fifty day moving average is $142.73 and its 200 day moving average is $139.68. The company has a market cap of $16.40 billion, a PE ratio of 25.13, a P/E/G ratio of 1.23 and a beta of 0.39. Neurocrine Biosciences, Inc. has a 52 week low of $122.14 and a 52 week high of $169.57.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the stock. Nilsine Partners LLC purchased a new position in shares of Neurocrine Biosciences in the fourth quarter valued at $1,197,000. Ruffer LLP purchased a new position in Neurocrine Biosciences during the fourth quarter worth about $2,479,000. Korea Investment CORP grew its position in Neurocrine Biosciences by 94.3% during the third quarter. Korea Investment CORP now owns 71,689 shares of the company’s stock worth $10,064,000 after buying an additional 34,800 shares in the last quarter. Envestnet Asset Management Inc. grew its position in Neurocrine Biosciences by 2.4% during the third quarter. Envestnet Asset Management Inc. now owns 202,846 shares of the company’s stock worth $28,476,000 after buying an additional 4,807 shares in the last quarter. Finally, CIBC Private Wealth Group LLC grew its position in Neurocrine Biosciences by 17,250.0% during the third quarter. CIBC Private Wealth Group LLC now owns 7,981 shares of the company’s stock worth $1,120,000 after buying an additional 7,935 shares in the last quarter. Institutional investors own 92.59% of the company’s stock.

Analyst Upgrades and Downgrades

NBIX has been the topic of several recent research reports. Canaccord Genuity Group increased their price target on Neurocrine Biosciences from $164.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Royal Bank Of Canada increased their price target on Neurocrine Biosciences from $180.00 to $183.00 and gave the stock an “outperform” rating in a report on Friday, May 29th. Citigroup increased their price target on Neurocrine Biosciences from $242.00 to $246.00 and gave the stock a “buy” rating in a report on Wednesday, May 6th. HC Wainwright increased their price target on Neurocrine Biosciences from $192.00 to $215.00 and gave the stock a “buy” rating in a report on Tuesday, April 7th. Finally, JPMorgan Chase & Co. increased their price target on Neurocrine Biosciences from $177.00 to $185.00 and gave the stock an “overweight” rating in a report on Friday, May 8th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $187.52.

About Neurocrine Biosciences

Neurocrine Biosciences (NASDAQ: NBIX) is a biopharmaceutical company based in San Diego, California, focused on developing treatments for neurological, endocrine and neuropsychiatric disorders. Since its founding in 1992, the company has pursued a research‐driven strategy aimed at addressing unmet medical needs in movement disorders, reproductive health and central nervous system conditions. Neurocrine’s operations encompass drug discovery, clinical development and commercialization activities.

The company’s lead marketed product, Ingrezza™ (valbenazine), is indicated for the treatment of tardive dyskinesia, a movement disorder associated with long-term antipsychotic use.